Homology Medicines, Inc. (FIXX)
| Market Cap | 371.05M |
| Revenue (ttm) | 31.42M |
| Net Income (ttm) | -94.44M |
| Shares Out | 50.36M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $6.47 |
| Previous Close | $6.50 |
| Change ($) | -0.03 |
| Change (%) | -0.46% |
| Day's Open | - |
| Day's Range | 6.46 - 6.63 |
| Day's Volume | 13,371 |
| 52-Week Range | 5.94 - 15.52 |
Homology Medicines (FIXX) delivered earnings and revenue surprises of 96.92% and 3681.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End -
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Data From Company's PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations -
- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership -
Dilution is on the way thanks to the company's latest stock offering.
BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for...
BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subjec...
Homology Medicines (FIXX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...
Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End -
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing...
- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication -
- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease -
Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102...
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -
Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors to Know Ab...
- Marked Reductions in Phe Observed at Two Dose s -
Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
San Francisco, California--(Newsfile Corp. - October 29, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...
San Francisco, California--(Newsfile Corp. - October 27, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...
HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers
Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hom...
San Francisco, California--(Newsfile Corp. - October 20, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...
San Francisco, California--(Newsfile Corp. - October 16, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inv...
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz continues its investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of in...
New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homolo...
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTIONS--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of inv...
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIX...
BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual confer...
Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Executive with Extensive Rare Disease Expertise in Global Finance and Commercial Operations -
Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications -
- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing for PKU -
Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for Adults with PKU -
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
About FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the live... [Read more...]
| Industry Biotechnology | Founded 2015 |
| CEO Arthur Tzianabos | Employees 205 |
| Stock Exchange NASDAQ | Ticker Symbol FIXX |
Financial Performance
In 2020, FIXX's revenue was $2.70 million, an increase of 62.18% compared to the previous year's $1.67 million. Losses were -$128.69 million, 23.8% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 23.60, which is an increase of 264.76% from the latest price.